Table 2

Recent clinical targeted toxin trialsa

AgentDiseaseResponseToxicitiesRef.
ONTAKCTCL22/71VLSb
HN6600Gliomas9/15CNS(13)
LMB-2HCL4/4Liver(12)
B43-PAPALL9/19VLS(8)
IgG-RFB4-dgANHL6/25VLS(41–43)
Fab′-RFB4-dgANHL5/14VLS(5)
Ber-H2-SO6HD5/12VLS(23)
TP40Bladder cancer8/43None(19)
Anti-B4-bRNHL8/59Liver(9, 44)
H65-RTACTCL4/14VLS(25)
3A1-dgRTAT-LGL, T-ALL2/11VLS(28)
DAB486IL2CTCL4/19Liver(45)
IgG-HD37-dgANHL3/32VLS, acrocyanosis(7)
LMB-1Carcinomas2/38VLS(1)
Xomazyme-791Colon cancer2/16VLS(21)
T101-RTACLL2/18VLS(24)
Anti-CD25-dgAHD2/15VLS(11)
N901-bRSCLC1/21VLS(18)
260F9-rABreast cancer1/9Schwann, VLS(22, 46)
XMMME-001-RTAMelanoma1/22VLS(26)
Erb-38Carcinomas0/8Liver(30)
OVB3-PEOvarian cancer0/23CNS(27)
LMB-7Carcinomas0/54Liver, kidneyc
Anti-Tac-PEATL0/4Liver(10)
454A12-rAAdenocarcinoma0/20CNS(14)
454A12-rALeptomeningeal cancer0/8Arachnoid(47)
DAB389EGFBreast cancer0/43Liver(20)
BR96(sFv)PE40Breast cancerTE
LMB-9CarcinomasTE
DTGMAMLTE
BL22HCL, CLL, HDTE
TXU-PAPTALLTE
IL4(38-37)PE38KDELGliomasTE
HuM195-rGelAMLTE
  • a AML, acute myeloid leukemia; TALL, T-cell acute lymphoblastic leukemia; NHL, non-Hodgkin’s lymphoma; SCLC, small cell lung carcinoma; T-LGL, T-cell large granular lymphocyte leukemia; TE, too early; CNS, central nervous system.

  • b E. Olsen, M. Duvic, A. Frankel, Y. Kim, A. Martin, E. Vonderheid, B. Jegasothy, G. Wood, M. Gordon, P. Heald, A. Oseroff, L. Pinter-Brown, G. Bowen, T. Kuzel, D. Fivenson, F. Foss, M. Glode, A. Molina, E. Knobler, S. Stewart, K. Cooper, S. Stevens, F. Craig, J. Reuben, P. Bacha, and J. Nichols. Pivotal Phase III trial of two dose levels of DAB389IL2 (ONTAK) for the treatment of cutaneous T-cell lymphoma, submitted for publication.

  • c L. H. Pai-Scherf, D. Pearson, R. Wittes, M. C. Willingham, and I. Pastan. A Phase I study of LMB-7,[ B3(Fv)PE38], a recombinant single-chain immunotoxin for advanced solid tumors, submitted for publication.